Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Myalepta metreleptin Leptin deficiency in lipodystrophy Reimburse with clinical criteria and/or conditions Complete
Myfembree relugolix, estradiol, and norethindrone acetate Management of heavy menstrual bleeding associated with uterine fibroids Pending
Myfortic Mycophenolate sodium Organ rejection in allogeneic renal transplants, Prophylaxis List in a similar manner to other drugs in class Complete
Myinfla colchicine Atherothrombotic events in coronary artery disease Do not reimburse Complete
Mylotarg Gemtuzumab Ozogamicin Acute Myeloid Leukemia (AML) Reimburse Complete
Myozyme Alglucosidase Pompe's disease List with clinical criteria and/or conditions Complete
Myrbetriq Mirabegron Overactive bladder List with criteria/condition Complete
Myrbetriq Mirabegron Overactive bladder Withdrawn
N/A eltrombopag Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Complete
N/A dapagliflozin Chronic kidney disease Reimburse with clinical criteria and/or conditions Complete